Could a common supplement and an HIV drug unlock oral ketamine for depression?

NCT ID NCT07462559

Not yet recruiting Knowledge-focused Sponsor: Helsinki University Central Hospital Source: ClinicalTrials.gov ↗

First seen Mar 11, 2026 · Last updated May 22, 2026 · Updated 11 times

Summary

This study looks at whether cannabidiol (CBD) and cobicistat (a drug that boosts other medications) can increase the amount of ketamine that reaches the bloodstream when taken by mouth. Ketamine is used for hard-to-treat depression but is usually given by IV because oral doses are poorly absorbed. The trial will involve 12 healthy volunteers who take a small oral dose of ketamine alone, with CBD, with cobicistat, or with both. Researchers will measure ketamine levels in the blood and monitor side effects to see if this combination could make oral ketamine a practical treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Department of Clinical Pharmacology

Helsinki, Finland

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DRUG-DRUG INTERACTION